News

November 10, 2022

CH Innovations and Catalytic Impact Foundation invest in DeckTherapeutics

September 20, 2022

DeckTherapeutics appoints Professor Yechezkel Barenholz, PhD to its Board of Directors

September 13, 2022

DeckTherapeutics appoints Dr. Larry Gold to the Board of Directors

September 5, 2022

DeckTherapeutics’ technology platform featured in The Wall Street Journal

July 8, 2022

DeckTherapeutics awarded research grant for studies of THDG3 in higher animals

October 21, 2021

Dr. Rebecca Juliano joins DeckTherapeutics as Clinical Advisor

August 3, 2021

DeckTherapeutics announces grant of patent

January 7, 2021

DeckTherapeutics announces the formation of Scientific Advisory Board

January 1, 2021

DeckTherapeutics participates in Biotech Showcase

December 11, 2020

DeckTherapeutics appoints new CEO

December 1, 2020

DeckTherapeutics obtains exclusive license to omega-3 IPR from DSM Nutrition

March 30, 2020

DeckTherapeutics obtains exclusive license to omega-3 IPR from the United States Army